Evidence map›Paper›PMID 25119890›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2014

The nuclear envelope: an intriguing focal point for neurogenetic disease.

Howard J Worman, William T Dauer

Abstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Dystonia: Insights into Mechanisms and Novel Therapeutics.Current neurology and neuroscience reports · 2026
    Review
  2. Review
  3. Congenital myasthenic syndrome due to aBrain communications · 2020
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. LINCing defective nuclear-cytoskeletal coupling and DYT1 dystonia.Cellular and molecular bioengineering · 2016
    Article
  13. Review
  14. Neurogenetic disease: genes, mechanisms, and future promise.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Howard J WormanDepartment of Medicine and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, 10032, USA, hjw14@columbia.edu.
William T Dauer

Funding

Pathogenesis of Emery-Dreifuss Muscular DystrophyR01AR048997 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WORMAN, HOWARD J · 2003 to 2024
$7.1M
Nucleocytoplasmic Interactions and Dynamics in Emery-Dreifuss Muscular DystrophyR01NS059352 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WORMAN, HOWARD J · 2007 to 2011
$1.9M
TorsinA function and dystonia-related dysfunction in developing and mature CNSR01NS077730 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAUER, WILLIAM T. · 2013 to 2017
$1.9M
The Nucleocytoskeleton in Progeria and AgingR01HD070713 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GUNDERSEN, GREGG G, WORMAN, HOWARD J · 2011 to 2015
$1.7M
Preclinical Development of Novel MEK1/2 Inhibitors to Treat Inherited CardiomyopaR41TR001008 · NCATS · CHEMINPHARMA, LLC · PI KHIRE, UDAY R · 2013 to 2013
$105k
NCATS NIH HHS R41 TR001008NCATS NIH HHS R41TR001008NIAMS NIH HHS R01 AR048997NIAMS NIH HHS R01AR048997NICHD NIH HHS R01 HD070713NICHD NIH HHS R01HD070713NINDS NIH HHS R01 NS059352NINDS NIH HHS R01NS059352NINDS NIH HHS R01 NS077730NINDS NIH HHS R01NS077730
6 · The paper itself

Abstract

Mutations in genes encoding nuclear envelope proteins cause a wide range of inherited diseases, many of which are neurological. We review the genetic causes and what little is known about pathogenesis of these nuclear envelopathies that primarily affect striated muscle, peripheral nerve and the central nervous system. We conclude by providing examples of experimental therapeutic approaches to these rare but important neuromuscular diseases.

Indexed as

AnimalsCentral Nervous System DiseasesGenetic TherapyHumansLamin Type AMuscular DystrophiesNuclear EnvelopePeripheral Nervous System DiseasesLamin Type ALMNA protein, human

Identifiers

PMID25119890
PMCPMC4391386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.